MedTrace Logo

A Study of Inhaled Atropine Sulfate in Healthy Adults

NCT00947596 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2010-08-12

No results posted yet for this study

Summary

MicroDose Defense Products, LLC is developing an atropine dry powder inhaler (ADPI). This pilot study compares the pharmacokinetics (PK) of inhaled dry powder atropine as delivered by the ADPI to atropine delivery from the AtroPen autoinjector.

Conditions

  • Organophosphorus Poisoning

Interventions

DRUG

atropine sulfate

dry powder for inhalation

DRUG

atropine sulfate

intramuscular injection

Sponsors & Collaborators

  • University of Pittsburgh

    collaborator OTHER

  • U.S. Army Space and Missile Defense Command

    collaborator FED

  • MicroDose Defense Products L.L.C.

    lead INDUSTRY

Principal Investigators

  • Michael Donahoe, M.D. · Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh

  • Timothy Corcoran, Ph.D. · Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-07-31
Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00947596 on ClinicalTrials.gov